In addition, a post hoc analysis of SURPASS-4 by Heerspink et al. shows that in participants with type 2 diabetes mellitus with high cardiovascular risk, those receiving the GIP/GLP-1R dual agonist, tirzepatide, had a significantly lower rate of composite renal endpoints, a significantly slower rate of decline in eGFR and a significantly lower urinary albumin creatinine value compared to those receiving glargine insulin [36]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.